Search Results

TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, announced that Gedeon Richter selected Trial Interactive’s award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) and Sumitomo Pharma Switzerland GmbH (‘SMPS’) today announce that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO®.

AbbVie and Gedeon Richter Plc. announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.

Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

IO Biotech announced that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate.